S166: MAGROLIMAB IN COMBINATION WITH AZACITIDINE FOR PATIENTS WITH UNTREATED HIGHER-RISK MYELODYSPLASTIC SYNDROMES (HR MDS): 5F9005 PHASE 1B STUDY RESULTS

• D. A. Sallman,
• M. M. Al Malki,
• A. S. Asch,
• E. S. Wang,
• J. G. Jurcic,
• T. J. Bradley,
• I. W. Flinn,
• D. A. Pollyea,
• S. N. Kambhampati,
• T. N. Tanaka,
• J. F. Zeidner,
• G. Garcia-Manero,
• D. Jeyakumar,
• L. Gu,
• A. Tan,
• M. Chao,
• C. O’Hear,
• I. Lal,
• P. Vyas,
• N. Daver

Affiliations

D. A. Sallman

1 Moffitt Cancer Center, Tampa

M. M. Al Malki

2 City of Hope National Medical Center, Duarte

A. S. Asch

3 Stephenson Cancer Center, Oklahoma University Health, Oklahoma City

E. S. Wang

4 Roswell Park Comprehensive Cancer Center, Buffalo

J. G. Jurcic

5 Columbia University Medical Center, New York

T. J. Bradley

6 Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami

I. W. Flinn

7 Tennessee Oncology, Nashville

D. A. Pollyea

8 University of Colorado School of Medicine, Denver

S. N. Kambhampati

9 Sarah Cannon Research Institute, Kansas City

T. N. Tanaka

10 University of California San Diego Moores Cancer Center, San Diego

J. F. Zeidner

11 Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill

G. Garcia-Manero

12 The University of Texas MD Anderson Cancer Center, Houston

D. Jeyakumar

13 University of California Irvine, Orange

L. Gu

14 Gilead Sciences, Inc., Foster City, United States of America

A. Tan

14 Gilead Sciences, Inc., Foster City, United States of America

M. Chao

14 Gilead Sciences, Inc., Foster City, United States of America

C. O’Hear

14 Gilead Sciences, Inc., Foster City, United States of America

I. Lal

14 Gilead Sciences, Inc., Foster City, United States of America

P. Vyas

15 Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, United Kingdom

N. Daver

12 The University of Texas MD Anderson Cancer Center, Houston